AlzeCure’s ACD440 Pain Therapy Receives FDA Orphan Drug Designation

AlzeCure Pharma AB (publ), a Swedish pharmaceutical company focused on treatments for nervous system disorders including Alzheimer’s and pain, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to its pain candidate ACD440.

ACD440 is being developed as a topical gel targeting chronic peripheral neuropathic pain and is currently moving toward pivotal Phase II/III clinical trials. The FDA’s orphan drug designation applies specifically to ACD440’s potential use in treating erythromelalgia, a rare and debilitating disease characterized by intense burning pain, redness, and swelling typically in the extremities. Erythromelalgia affects roughly 13 in 100,000 people and currently has no approved treatments.

“We are very pleased with this recognition,” said Märta Segerdal, Chief Medical Officer of AlzeCure Pharma. “Combined with positive FDA feedback on our pre-IND application, this designation enhances our ability to bring effective treatment options to severely affected patients.”

ACD440 is a first-in-class TRPV1 antagonist, developed as a topical therapy to provide sustained local pain relief with minimal systemic exposure. The drug candidate was strategically in-licensed and is based on Nobel Prize–winning science from 2021.

Martin Jönsson, CEO of AlzeCure Pharma, emphasized the benefits of orphan drug status, including accelerated approval pathways, priority review, and extended market exclusivity, which will strengthen the company’s competitive position and out-licensing potential. He also highlighted the high market value of orphan drugs in the U.S., with median annual treatment costs around SEK 2 million.

AlzeCure is preparing to advance ACD440 into later-stage clinical trials, aiming to address the significant unmet need in erythromelalgia and other neuropathic pain conditions.